About: Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland
Creator	Räsänen, Sirpa Vesikari, Timo Paloniemi, Minna Hemming, Maria Huhti, Leena Salminen, Marjo
Source	Medline; PMC
abstract	Universal rotavirus (RV) vaccination is expected to reduce hospitalizations for acute gastroenteritis (GE) of children by eliminating most of severe RVGE, but it does not have any effect on norovirus (NV), the second most common causative agent of GE in children. After the introduction of the RV vaccine into the National Immunization Programme (NIP) of Finland in 2009, we conducted a prospective 2-year survey of GE in children seen in Tampere University Hospital either as outpatients or inpatients and compared the results with a similar 2-year survey conducted prior to NIP in the years 2006–2008. Compared with the pre-NIP 2-year period, in 2009–2011, hospitalizations for RVGE were reduced by 76 % and outpatient clinic visits were reduced by 81 %. NVGE showed a slight decreasing trend and accounted for 34 % of all cases of GE seen in hospital in pursuance of RVGE having decreased to 26 % (down from 52 %). In cases admitted to the hospital ward, RV accounted for 28 % and NV accounted for 37 %.The impact of RV vaccination was reflected as a 57 % decrease in all hospital admissions and 62 % decrease in all outpatient clinic visits for GE of any cause. Conclusion: RV vaccination in NIP has led to a major reduction of hospital admissions and clinic visits due to RVGE, but has had no effect on NVGE. After 2 years of NIP, NV has become the leading cause of acute GE in children seen in hospital.
has issue date	2013-01-30(xsd:dateTime)
bibo:doi	10.1007/s00431-013-1945-3
bibo:pmid	23361964
has license	no-cc
sha1sum (hex)	77c8d82878c5d86f6caf84b5ef6c29f7a5e2e9da
schema:url	https://doi.org/10.1007/s00431-013-1945-3
resource representing a document's title	Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland
has PubMed Central identifier	PMC7086648
has PubMed identifier	23361964
schema:publication	Eur J Pediatr
resource representing a document's body	covid:77c8d82878c5d86f6caf84b5ef6c29f7a5e2e9da#body_text
is schema:about of	named entity 'hospital' named entity 'Finland' covid:arg/77c8d82878c5d86f6caf84b5ef6c29f7a5e2e9da named entity 'outpatient clinic' named entity 'leading' named entity 'conducted' named entity 'vaccine' named entity 'severe' named entity 'visits' named entity '2009' named entity 'hospital ward' named entity 'Tampere University Hospital' named entity 'RotaTeq' named entity 'Finland' named entity 'genotype' named entity 'vaccine' named entity 'PCR' named entity 'RotaTeq' named entity 'vaccine' named entity 'antigens' named entity 'Pirkanmaa Hospital District' named entity 'gene' named entity 'urban area' named entity 'GenBank' named entity 'Food-borne' named entity 'wild-type' named entity 'Viruses' named entity 'virus' named entity 'genotype' named entity 'Europe' named entity 'G3P' named entity 'viruses' named entity 'genotype' named entity 'Immunization' named entity 'causative agent' named entity 'viruses' named entity 'G1P' named entity 'statistically significant' named entity 'vaccination program' named entity 'RotaShield' named entity 'outpatient' named entity 'statistically significant' named entity 'pediatric ward' named entity 'Finland' named entity 'RotaTeq' named entity 'genotypes' named entity 'Finland' named entity 'causative agent' named entity 'outpatient' named entity 'reassortant' named entity 'RT-PCR' named entity 'Finland' named entity 'hospital ward' named entity 'astrovirus' named entity 'Finland' named entity 'pediatric ward' named entity 'vaccines' named entity 'genotype' named entity 'RotaShield' named entity 'G3P' named entity 'adenovirus' named entity 'RVs' named entity 'outpatient' named entity 'noroviruses' named entity 'RotaTeq' named entity 'wild-type' named entity 'Tampere University Hospital' named entity 'outpatient' named entity 'vaccines' named entity 'Merck & Co. Inc.' named entity 'legal guardian' named entity 'G1P' named entity 'symptom' named entity 'VP7' named entity 'G3P' named entity 'Europe'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software